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IntroductIon
The UK has poor cancer outcomes when 
compared with most other European 
countries, with an estimated additional 
10 000 deaths annually.1,2 Much of this is 
attributed to diagnostic delay, which can 
reflect later presentations for medical 
attention by symptomatic patients, or delays 
after presentation. Nine out of 10 patients 
with cancer present with symptoms, and 
most present to primary care.3 Initiatives 
to expedite diagnosis include urgent 
referral pathways (established in Spain and 
Denmark as well as the UK); guidance on 
selection of patients for urgent referral or 
investigation (in Denmark and the UK),4 
and, in the UK, the creation of the National 
Awareness and Early Diagnosis Initiative 
(NAEDI) in 2008.5 A criticism of urgent 
referral guidance has been that it describes 
common high-risk presentations of cancer, 
neglecting patients who present with ‘low-
risk-but-not-no-risk’ symptoms.6 Such 
patients have longer times to diagnosis and 
worse mortality.7 
A possible solution is to develop clinical 
decision support instruments to help GPs 
identify patients for investigation. One such 
instrument is the Risk Assessment Tool 
(RAT), derived from primary care cohort 
studies and validated on separate patient 
cohorts.8,9 These give risk estimates for 
patients aged >40 years presenting to 
primary care with symptoms of possible 
cancer, for single symptoms, pairs of 
symptoms and repeat attendances with 
the same symptom. The values are 
colour-coded to aid interpretation. An 
example is shown in Figure 1. A small 
pilot evaluation of a similar scoring system 
had been encouraging, suggesting that 
interested GPs would be motivated to use 
RATs.10 The RATs were designed to be an 
adjunct to National Institute for Health and 
Clinical Excellence (NICE) guidance, which 
described moderately high-risk symptom 
profiles warranting urgent investigation.4
The study evaluated the utility and 
acceptability of RATs for suspected bowel 
and lung cancer, measuring their use, their 
incorporation into the clinical encounter, 
and their effect on resource use and new 
cancer diagnoses. The study was conducted 
in two phases: a quantitative and qualitative 
phase.
Method
Cohort study
All 28 English cancer networks were offered 
participation, from which seven were 
selected to ensure a broad geographical 
spread. Each network identified a GP 
cancer lead and recruited local practices, to 
which RATs were supplied in two formats; 
as mousemats and desktop flipcharts. The 
electronic version of the paper shows all 
three RATs, along with the instructions 
on their use, exactly as supplied to the 
participants. Lung and bowel RATs were 
selected, as both cancers are common, 
and each has an excess annual mortality of 
nearly 1000 deaths.11
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Abstract
Background 
Diagnostic delay is deemed to account for an 
estimated 5000 to 10 000 extra cancer deaths 
each year in the UK. Many cancer patients do 
not have symptoms meeting national referral 
criteria for rapid investigation. Risk assessment 
tools (RATs) have been developed to assist GPs 
in selecting patient for cancer investigation.
Aim
To assess the usability and acceptability of lung 
and colorectal RATs, as well as subsequent 
resource use and cancer diagnoses. 
design and setting
Cohort study with nested qualitative study with 
614 GPs from 165 practices in seven English 
cancer networks were provided with RATs 
applicable to patients aged ≥40 years with bowel 
or respiratory symptoms. In-depth interviews 
were conducted with 34 individuals (11 project 
managers and 23 GPs). 
Method
The study measured the number of RATs used, 
and subsequent cancer investigations and 
diagnoses, over a 6-month period and compared 
these with the previous 6 months. 
results
A total of 2593 RATs (1160 lung, 1433 colorectal) 
were completed. Compared with the preceding 
6 months, there were 292 more chest X-rays, 
104 extra 2-week chest clinic appointments, 
and 47 additional diagnoses of lung cancer. For 
suspected colorectal cancer, there were 304 
more 2-week referrals, 270 more colonoscopies, 
and 10 more cancers identified. RATs appeared 
to help GPs in their selection of patients for 
cancer investigation. Users reported that RATs 
helped to confirm a need for investigation as 
well as allowing reassurance when investigation 
was not needed. 
conclusion
Use of RATs in primary care was accompanied 
by increased diagnostic activity and additional 
cancer diagnoses. 
Keywords
colorectal cancer; diagnosis; lung cancer; 
primary health care.
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Data for the evaluation were collected 
using an A4 pad that contained all three 
RATs (lung having one for smokers and 
one for non-smokers) on a single page. 
No specific recommendations were given 
about what level of cancer risk should be 
investigated. This was deliberately left to 
the individual GP’s discretion. The study 
defined investigation for cancer as a 2-week 
referral to the appropriate speciality, or a 
chest X-ray (CXR) in possible lung cancer. 
Cancer networks collected resource use 
and outcome data from practices and local 
trusts for the two 6-month periods before 
and after the distribution of RATs. 
Data analysis used simple descriptive 
statistics, with non-parametric analyses 
where appropriate: The study used Stata, 
how this fits in
The UK has poor cancer outcomes, some 
of which is blamed on delays in diagnosis. 
Decision support systems have been 
developed to help clinicians in primary care 
select patients for investigation of cancer, 
but they have not been studied. GPs are 
willing to use decision support systems for 
lung and colorectal cancers and usage is 
accompanied by an increase in diagnostic 
activity with additional cancers identified.
C
on
st
ip
at
io
n
0.42
0.81
D
ia
rr
ho
ea
0.94
1.1
1.5
R
ec
ta
l b
le
ed
in
g
2.4
2.4
3.4
6.8
Lo
ss
 o
f w
ei
gh
t
1.2
3.0
3.1
4.7
1.4
A
bn
or
m
al
 r
ec
ta
l e
xa
m
1.5
2.6
11
8.5
7.4
3.3
5.8
H
ae
m
og
lo
bi
n 
10
–1
3g
/d
l
0.97
1.2
2.2
3.6
1.3
2.2
2.7
PPV as a single
symptom
Constipation
Diarrhoea
Rectal 
bleeding
Loss of weight
Abdomina
pain
Abdominal
tenderness
H
ae
m
og
lo
bi
n 
<
10
g/
dl
2.3
2.6
2.9
3.2
4.7
6.9
>10
A
bd
om
in
al
 p
ai
n
1.1
1.5
1.9
3.1
3.4
3.0
A
bd
om
in
al
 te
nd
er
ne
ss
1.1
1.7
2.4
4.5
6.4
1.4
1.7
the top row gives the positive predictive value (PPV) for an individual feature. the cells along 
the diagonal relate to the PPV when the same feature has been reported twice. thus the 
constipation/constipation intersect is the PPV for colorectal cancer when a patient has attended 
twice (or more often) with constipation. other cells show the PPV when a patient has two 
different features.  For haemoglobin <10g/dl with abdominal tenderness, no controls in the 
original evaluation had this pair. It was scored as a PPV of >10%.  the yellow shading is when the 
PPV is above 1%. the amber shading is when the PPV is above 2.5%, which approximates to a risk 
of colorectal cancer of 10 times normal. the red shading is for PPVs above 5.0% approximating to 
a risk of 20 times normal
Figure 1. risk Assessment tool (rAt) 
for colorectal cancer.6
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(version 11). The evaluation was designed 
to provide 1600 completed RATs; this would 
have 95% power (5% 2-sided alpha) to 
identify a change in investigative behaviour 
from 5% to 10% of patients (colorectal) 
and 89% power for a change from 20% 
to 30% (lung smokers). The evaluation 
was not powered to identify change in 
the secondary outcomes of resource use, 
cancer diagnoses or staging.
Qualitative interviews
GP cancer leads in the participating 
networks, together with GP users from 
a purposeful sample of practices were 
approached to take part in in-depth 
telephone interviews to ascertain their 
perceptions and experiences of using 
the RATs in practice. The study selected 
participants to include areas of affluence 
and poverty, and practices with non-white 
patient populations ranging from 2–50%. 
Interviews were transcribed verbatim and 
a systematic qualitative methodology based 
on the Framework method of analysis was 
applied to the data.12 Close reading of each 
interview transcript and accompanying 
contextual and de-briefing notes was used 
to generate codes and cross-checking of 
the transcript coding between researchers 
was conducted.
reSultS
A total of 614 GPs from 165 practices were 
recruited. They completed 2720 RATs, of 
which 127 were subsequently excluded (60 
had been used in patients <40 years; 67 
had not identified the reported symptoms), 
leaving 2593 for analysis. Figure 2 shows 
RAT use over time. RATs were used in more 
females than males (1413 females (54.5%); 
1162 males (44.8%); 18 (0.7%) missing data; 
1007 RATs (38.8%) were used in patients 
aged ≥70 years. 
The commonest symptoms for which 
the 1433 colorectal RATs were used were: 
diarrhoea (588 (41%), of which 422 (72%) 
had a second documented symptom) 
and rectal bleeding (462 (32%), of which 
275 (60%) of had a second documented 
symptom). For the 1160 lung RATs, the 
commonest symptoms were cough (832 
(72%), of which 456 (55%) had a second 
documented symptom, and dyspnoea (280 
(24%), of which 266 (95%) had a second 
documented symptom). For 702 patients 
in whom a colorectal RAT was used, a 
2-Week Wait referral was made, with a 
further 337,11 being either admitted as an 
emergency or having an urgent (n = 144) or 
150
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Figure 2. rAt usage during the evaluation.
table 1. Investigations for colorectal and lung cancer before and during the evaluation
  2-week referrals  GP requested cXr  2-week referrals colonoscopies 
  for lung, n  (for ages >40 years), n  for colorectal, n (for ages >40 years), n
cancer network lung 6 months  6 months  colorectal rAts 6 months  6 months 
practices (n) rAts before   during before   during completed, n before   during before   during
NC London (19) 42 24 33 818 1015 114 95 144 246 324
SW London (14) 345 34 30 563 548 244 94 112 178 187
Sussex (42) 206 106 151 1549 1742 333 406 457 646 903
Three Countiesa (25) 40 29 37 1247 1204 175 148 156 233 259
York & Humber (25) 347 69 119 2294 2134 285 231 356 219 112
North Trent (26) 133 70 66 960 1080 248 199 252 240 247
NE Londona (14) 86 – – – – 122 – – – –
Total 1199 332 436 7431 7723 1521 1173 1477 1762 2032
Increase 31% 4% 26% 15%
Only 12 of the 25 practices in the Three Counties Cancer Network returned data on referrals and investigations for analysis in both periods. None was returned from North 
East London. CXR = chest X-ray. NC = north central. NE = north east. RAT = risk assessment tool. SW = south west.
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routine (n = 182) referral to an appropriate 
speciality. A CXR was recorded for 684 
(59%) patients in whom a lung RAT was 
completed: 10 others were admitted as an 
emergency, while 149, 32, and 55 patients 
had a 2-week, urgent, or routine referral to 
respiratory medicine, respectively. Some of 
these last three categories may have had a 
preceding CXR which the GPs omitted from 
the data collection form. The proportions 
being investigated greatly exceeded the 
estimated in the sample size calculations. 
The median (interquartile range [IQR]) risk 
estimate, expressed as a percentage risk 
of an underlying cancer, was 2.4% (IQR 1.5–
3.4) in those selected for investigation, and 
1.1% (IQR 0.6–1.8) in those not investigated: 
P<0.001, Mann Whitney test. 
GPs gave their own personal estimate 
of the risk of cancer as higher, lower, 
or the same as the RAT estimate, with 
12% considering the risk to be higher, and 
13% lower. If the GP considered the ‘true’ 
risk to be higher, they were more likely 
to investigate (odds of investigation 3.5: 
P<0.001), when compared to the group who 
estimated the risk to be the same. However, 
if GPs estimated the ‘true’ risk to be lower, 
they were no less likely to investigate (odds 
of investigation 0.93; P = 0.59).
Resource use and cancer diagnoses
These data are summarised in Table 1. One 
cancer network found it impossible to obtain 
the data for resource use, and a second 
network had similar problems for 13 of 
their practices. New lung cancer diagnoses 
increased from 127 in the 6 months before 
the evaluation to 174 during the pilot; a 37% 
rise. The proportion of stage 1 and stage 2 
cancers combined (as a proxy for potential 
cure) increased by 19% (from 26 to 31). New 
colorectal cancers increased by 76% (from 
134 to 144), a 7% rise. No significant change 
in staging was seen (data not shown). 
Qualitative interviews
Interviews were conducted with 23 GP 
responders who had personal experience 
of using the tool in practice: the study 
reports findings on how RATs were used 
to aid decision making related to referral 
(Box 1). To varying degrees RATs affected 
GPs’ referral thresholds and in turn, their 
decision making; for example, in several 
instances the tool was perceived to give 
more credence to a decision to refer 
that had already been made. For some 
responders, the tool urged referrals that 
may not have been made. At other times, 
the tool was used to confirm decisions not 
to refer. 
Several interviewees were surprised 
at the symptoms the RATs listed and 
some queried why particular symptoms/
combinations of symptoms should alert a 
referral, but the way in which the RATs led 
Box 1. Illustrative quotations from the interview study
referral thresholds
‘Mid-project we looked at our numbers and we felt that under the clause, would you have referred this 
patient if you hadn’t been using the risk assessment tool, there was a significant minority that said, you 
know, the tool had pushed them to a different decision ... it was 10–15% of people that may have waited 
longer if they hadn’t had the tool.’ (GPL/2)
‘I think our referral thresholds for lower GI have definitely gone down.’ (GPL/3)
‘I’d say particularly it got us thinking about patients with COPD, because, um, there’s a bit in the, ah, in the 
lung tool which is smokers with COPD saying they automatically should have a referral for a chest X-ray, 
and that made us think about how frequently we should do chest X-rays in our COPD patients.’ (GPL/8)
Questioning of practice
‘It did make us all [in the practice] think though that we should be a bit more careful with people that we 
put ... where we put rectal bleeding down to anal, um, conditions such as piles and things like that; you 
know, when you should really say, no, enough is enough and you should refer this patient.’ (GPL/8)
‘It reinforced key ideas in there about combination of symptoms and key symptoms, and it has certainly 
helped to stimulate debate at the practice about ... patients with anaemia, for example ... I think as an 
educational tool for a team, it’s also very useful ... when people actually study the detail they do gain 
knowledge from it and so it does confer a little bit more confidence in what to do in certain situations.’ 
(GP/6)
raising awareness of symptoms
‘Although I wasn’t sure it changed much of how I practice, um, it did prompt probably a few more referrals 
for multiple presentations of the same thing, like abdominal pain ... there were one or two new things that, 
um, most GPs really weren’t that aware of ... different combinations of symptoms.’ (GPL/7).
‘It is quite a useful checklist of symptoms, it reminds you to ask the patients the right things that are going 
to help you to make a better diagnosis or make a better decision about whether to refer them or not.’ 
(GPL/1)
decision making
‘If I had a patient with a vague set of symptoms then finding and using the tool showed that it was an 
amber, for instance, would just perhaps, while not encouraging a referral there and then, I might have 
followed up the patient in a different way, um, and so made sure that I kept in touch with them ... we [as a 
practice using the tool] were actually more proactive in saying, actually, I’d like to see you again, just to see 
how these symptoms are, um, rather than leaving it to the patient to contact us.’ (GPL/4).
‘Where someone’s come back a couple of times and you think, oh, I’ve safety-netted there, should I have 
done? But you go back and reflect on it and then think, actually, I don’t know that I should and, you know, 
phone the patient back and say, ‘actually, on reflection, I think I’ll send you’. So it’s a minority but I think in 
some cases where, perhaps you were safety-netting rather than referring, and then you have a little reflect 
and think, oh no, I will refer. So it’s a minority, but I think it is helpful.’ (GPL/3).
‘A lot of early cancer diagnosis is just, you know ... good basic basics ... always ask that question in the back 
of your mind ... could this be cancer? and then disprove it in your clinical assessment.’ (GPL/6).
the role of diagnostic aids in consultations
‘I don’t think you can ever protocolise or ... make a risk schedule that is better than, than looking at 
experience.’ (GP/11).
‘I think they all (risk assessment tools) have their place in the total overall assessment of the patient and 
probably none of the tools are ... of course, none of them are infallible, um, but I think it helps inform the 
decision. It does help.’ (GP/12).
‘This tool could be very useful ... [GPs] know the history of a patient, they know that that patient used to 
smoke, they know that patient is generally unwell ... they know the patient perhaps would be comforted by 
going to have a test or not ... not to send a patient because of the tool is a danger ... it must be an aid, and 
not a rooted instruction.’ (PM/4). 
‘What I teach my GP trainees is that actually you rely on your gut instinct to refer ... and so we do, but that’s 
where I could find this a being more of a kind of, an algorithm that would help you with ... patients that you 
feel they need the 2-week rule but you haven’t got quite the diagnostic criteria that fits the criteria for the 
2-week rule referral.’ (GP/4).
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GPs to question given ways of practice was, 
however, repeatedly described as positive, 
particularly in relation to referral thresholds. 
The tool thus encouraged a deeper level of 
thinking about symptom presentations and 
raised awareness of symptom patterns and 
combinations, thereby promoting actions 
such as ensuring patients returned earlier 
for review. 
The qualitative data confirm that the RATs 
brought about changes to GP practice. That 
said, although the tools were perceived 
overall to be a valuable aid to diagnosis, 
responders’ comments indicated the tools 
did not override clinical judgement, nor 
supersede other guidance; rather they 
were an adjunct to the diagnostic process. 
dIScuSSIon
This evaluation showed that clinical 
decision support tools (RATs) for lung and 
colorectal cancer are used by GPs to help 
select patients for investigation and/or 
referral. Use of RATs was accompanied 
by an increase in cancer investigations and 
urgent referrals and more cancers were 
diagnosed. 
Strengths and limitations
This evaluation has several limitations, 
the most important being that it was a 
before and after design. The timetable for 
implementation by the National Cancer 
Action Team (NCAT) of RATs for lung and 
colorectal cancer was driven by the need 
to address poor cancer outcomes, the 
desire to pilot what appeared a promising 
tool and to align the intervention to the 
first national public awareness campaign. 
As a result, the study cannot know to 
what extent the changes in investigative 
behaviour are due to RAT usage, though 
the changes in the outcome measures 
suggest there has been some effect, and 
the evidence from the qualitative data 
support the argument that behaviour did 
change. Some referrals clearly would have 
happened anyway, such as emergency 
admissions (RATs were not designed to 
facilitate these), and other patients may 
have been investigated at a later date, and 
the RAT has simply expedited this. There is 
an apparent disparity between the internal 
evaluation figures showing — for example 
— 702 2-week colorectal referrals, yet the 
external data identifying an increase of 304 
such referrals. This can be explained by 
several possibilities: the most likely being 
that many of the RAT-based referrals would 
have been made anyway, or perhaps made 
later. Secondly, the external data were 
collected at a practice level, so included any 
GPs in participating practices who did not 
personally use the RATs. Thirdly, seasonal 
changes may have affected the incidence 
of bowel and respiratory symptoms, 
prompting changes in referral numbers. 
The evaluation took place in the spring 
and summer of 2011 while the comparison 
data came from the autumn and winter of 
2010/2011. It was also disappointing two 
networks had difficulties with external data 
collection, although there is no reason to 
believe this introduced bias. Finally, the 
study did not collect data on patients in 
whom no RAT was performed, so the 
percentage of total consulting patients 
who had a RAT performed, or whether 
this differed between the sexes, cannot be 
estimated. 
Against this, the evaluation was large and 
well geographically spread, and is likely 
to be representative of English general 
practice. The qualitative study helped the 
study understand what was happening in 
consultations to produce the extra CXR and 
2-week referrals. 
Comparison with existing literature
Almost one-half of patients in whom a 
colorectal RAT was used were subsequently 
referred under the 2-week system, with 
another quarter having alternative (but 
relevant) referrals. Even more lung patients 
were investigated, with nearly 60% having a 
CXR. Those not being X-rayed were of lower 
risk, and presumably too low in the GP’s 
view to warrant investigation. Interpretation 
of this depends upon whether GPs were 
using RATs on every patient aged >40 years 
with a bowel or respiratory symptoms, or 
whether they were being selective in using 
the RATs in patients deemed to be at higher 
risk of cancer. The study did not collect 
data on symptomatic patients who had 
no RAT completed. It is likely there were 
many of these, as approximately 2.6% of 
GP consultations have a bowel symptom 
recorded in the GP records.10 Furthermore, 
isolated symptoms documented on the 
RATs were in the minority. Together this 
suggests GPs were using RATs in the more 
complex presentations of symptoms, which 
is their purpose; data from the interviews 
support this interpretation. 
The increase in use of diagnostic 
resources was moderate: approximately 
270 additional colonoscopies. As there is no 
simple diagnostic test for colorectal cancer 
for use in primary care, suspicion of the 
cancer has either to be followed by review 
in primary care with referral on persistence 
or worsening of symptoms (so-called 
‘safety netting’), or proceeding without 
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delay to imaging of the bowel, usually by 
colonoscopy, or perhaps CT colonography.13 
More is spent in England on diagnosis 
of colorectal cancer than on treatment: 
reflecting the number of colonoscopies 
required to identify one cancer.14 Ten 
additional cancers were identified during 
this evaluation. The study know that 270 
more colonoscopies were performed during 
the study, but do not know if all the ‘extra’ 
colonoscopies were in patients in whom a 
RAT was used. If, for simplicity, it can be 
assumed they were, then the yield of these 
‘extra’ colonoscopies was approximately 
4%, which is similar to the risk estimates 
for many of the symptomatic presentations 
on the RAT. In other words, the figures are 
about what could be expected. It will require 
health-economic analyses to determine if 
such a yield is cost-effective. 
In contrast, the lung results are better 
than would be expected. The investigation of 
possible lung cancer in primary care is very 
different from that of possible colorectal 
cancer. GPs have easy access to CXRs, 
which have good performance in terms 
of sensitivity and specificity. A 2-week 
referral generally follows an abnormal 
CXR, although as there are a small 
percentage of false-negatives CXRs in lung 
cancer,15 national guidance recommends 
referral without an abnormal CXR in a few 
circumstances.4 The external data suggest 
that around 300 additional CXRs had been 
taken: for these to have identified 47 new 
cancers is unrealistic. Seasonal issues may 
be relevant. Respiratory symptoms are 
much more common in the winter, so the 
‘true’ increase in CXR usage may have been 
higher: certainly the GPs reported taking at 
least 684 in patients who had entered the 
study, although some of these may well have 
been requested even if RATs had not been 
used. Even so, the considerable increase in 
new cancer diagnoses (some of which were 
of an early stage, and potentially curable) is 
in the right direction, although very unlikely 
to be wholly a result of introduction of RATs.
Implications for research and practice
There is considerable interest in the use of 
clinical decision support tools to aid earlier 
diagnosis of cancer. The study shows that 
RATs encourage GPs to think about referral 
thresholds, prompt them to investigate and 
may lead to earlier diagnosis. Increased 
resources are being given to English 
cancer diagnostics in 2012;16 the results 
suggest that RATs have a role in ensuring 
the efficient use of both this resource 
and specialist referral, thus supporting 
the quality, innovation, productivity and 
prevention agenda of the NHS.17 
Use of RATs may bring a mortality 
benefit, although the size of this is difficult to 
quantify. Nevertheless, the National Cancer 
Action Team, through cancer networks, has 
distributed colorectal and lung RATs to all 
English GPs, following unpublished interim 
results from this evaluation. As well as its 
potential clinical benefits, this dissemination 
represents an excellent opportunity to study 
whether diagnostic tools are assisting GPs 
to investigate for possible cancer, although 
once again observational methods will have 
to be used. 
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